International Patient Service (24/7) · WhatsApp +86 138 1783 1623
CLINICAL TECHNOLOGIES
Frontier pediatric technologies already accessible in China — from dual-target CAR-T and haploidentical transplant to proton therapy with pediatric anesthesia teams.
Showing 9 of 9
China runs the world's largest pediatric CAR-T clinical program — CD19/CD22 products achieve >90% complete remission in relapsed/refractory childhood B-ALL, at roughly one third of Western costs.
Haploidentical transplant protocols pioneered in China enable virtually every child to find a donor — curative for leukemia, thalassemia and immune deficiencies, with outcomes matching matched-sibling transplants.
Proton beam spares growing tissues — critical for children with brain tumors and sarcomas. Shanghai's proton & heavy-ion center operates dedicated pediatric protocols with anesthesia support for young children.
Superselective intra-arterial chemotherapy delivers drug directly to the eye — saving both life and sight. The Xinhua Hospital program reports >99% survival with ~80% eye preservation.
From nusinersen to base-editing trials for thalassemia, innovative rare disease therapies are increasingly accessible in China through national reimbursement and the Boao Lecheng pilot zone.
Neonatal arterial switch, single-ventricle staging and minimally invasive repair — China's top centers operate on newborns as small as 2 kg with >98% survival for complex defects.
Stereo-EEG guided resection, laser ablation and vagus nerve stimulation give drug-resistant epilepsy children a real chance at seizure freedom.
Level III NICUs rescue extremely preterm infants from 24 weeks — with therapeutic hypothermia, neonatal surgery and inter-hospital ECMO transport.
Ultra-low-dose pediatric protocols on total-body PET-CT and 3T MRI — child-friendly suites with sedation teams make scans safer and calmer.
Sunny Assistant
MedBridge Pediatrics AI guide
AI assistant — not medical advice. For diagnosis & treatment, request a free case review.
